Articles By Jiha Lee, MD
La EPI-AR en la era del 'Treat-to-Target': la sonda sobre el tórax
By Jiha Lee, MD
En el EULAR 2026, los ponentes de la sesión “Catching Your Breath: Unravelling RA Associated Interstitial Lung Disease (ILD)” señalaron que la enfermedad pulmonar intersticial asociada a la artritis reumatoide (EPI-AR) es uno de los pocos resultados que no mejoran en la era de los biológicos. Tres resúmenes refuerzan este mensaje y abogan por una herramienta de cribado práctica y de bajo coste que ya está en manos de la mayoría de los reumatólogos.
Read Article
RA-ILD in the Age of Treat-to-Target: Put the Probe on the Chest
By Jiha Lee, MD
At EULAR 2026, speakers of the session “Catching Your Breath: Unravelling RA Associated Interstitial Lung Disease (ILD)” noted RA-ILD is one of the few outcomes not improving in the biologic era. Three abstracts reinforce that message and make the case for a practical, low-cost screening tool that is already in most rheumatologists’ hands.
Read Article
Novedades en artritis psoriásica: Un recorrido vertiginoso
By Jiha Lee, MD
En la sesión "Novedades en artritis psoriásica" del congreso EULAR 2026, el profesor Dennis McGonagle (Leeds, Reino Unido) ofreció a la audiencia un recorrido vertiginoso pero compacto por este campo, abordando tres temas: la fisiopatología de la artritis psoriásica (APs), la individualización del manejo clínico y la investigación emergente y las direcciones futuras.
Read Article
What’s New in Psoriatic Arthritis: A Whirlwind Tour
By Jiha Lee, MD
At the "What Is New in Psoriatic Arthritis" session at EULAR 2026, Professor Dennis McGonagle (Leeds, UK) took the audience on a whirlwind yet compact tour of the field, touching on three themes: the pathophysiology of PsA, individualization of clinical management, and emerging research and future directions.
Read Article
Un campo al que le ha llegado su momento: Lanzamiento del Grupo de Estudio de la EULAR sobre Reumatología Geriátrica
By Jiha Lee, MD
Una parte sustancial de los pacientes atendidos en las clínicas de reumatología son ahora adultos mayores que viven con multimorbilidad, polifarmacia, fragilidad, deterioro cognitivo, limitación funcional y prioridades de salud contrapuestas. Esta semana, en el EULAR 2026 en Londres, el Grupo de Estudio de Reumatología Geriátrica de EULAR celebra su reunión inaugural. El lanzamiento marca un paso importante para un campo que ha sido visible en la práctica clínica, pero menos visible en las estructuras profesionales.
Read Article
A Field Whose Time Has Come: Launching the EULAR Study Group on Geriatric Rheumatology
By Jiha Lee, MD
A substantial portion of patients seen in rheumatology clinics are now older adults living with multimorbidity, polypharmacy, frailty, cognitive impairment, functional limitation, and competing health priorities. This week at EULAR 2026 in London, the EULAR Study Group on Geriatric Rheumatology holds its inaugural meeting. The launch marks an important step for a field that has been visible in clinical practice, but less visible in professional structures.
Read Article
Ianalumab Shows Phase 3 Success in Sjögren’s: Is It Clinically Meaningful?
By Jiha Lee, MD
On the final day of ACR25, late-breaking abstract #24 drew particular attention, presenting results from the first positive Phase 3 trials of a potential systemic treatment for a disease that has long lacked one.
Read Article
Accelerated Aging in Rheumatic Disease: From Biology to Lifestyle Intervention
By Jiha Lee, MD
At ACR 2025, the session “27M02: Nutrition for Rheumatic Disease: Where Aging Biology, Sarcopenia, and Diet Intersect” invited the audience to view rheumatic disease through the lens of biological aging and to consider how nutrition and exercise can serve as integrative lifestyle interventions.
Read Article
Rheumatology’s Blind Spot: The Persistent Exclusion of Older Adults
By Jiha Lee, MD
As the population ages globally, rheumatologists are caring for an increasingly older patient population more than ever before. In RA alone, nearly 40 percent of patients are now aged 65 years or older. Yet the evidence guiding our treatment decisions continues to come from studies that rarely include them, giving rise to a fundamental question: do we really know how best to treat older adults with rheumatic diseases?
Read Article
ICYMI: Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA
By Jiha Lee, MD
At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory rheumatoid arthritis (RA), a term now being used to describe a subset of patients who have failed to respond to five or more biologic or targeted synthetic DMARDs. This new classification, derived from recent multinational registry data, represents a significant step in refining our understanding and management of the most treatment-resistant forms of RA.
Read Article
